MX355234B - Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). - Google Patents

Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).

Info

Publication number
MX355234B
MX355234B MX2014013092A MX2014013092A MX355234B MX 355234 B MX355234 B MX 355234B MX 2014013092 A MX2014013092 A MX 2014013092A MX 2014013092 A MX2014013092 A MX 2014013092A MX 355234 B MX355234 B MX 355234B
Authority
MX
Mexico
Prior art keywords
ctla
variants
stability
monthly
potency
Prior art date
Application number
MX2014013092A
Other languages
English (en)
Other versions
MX2014013092A (es
Inventor
Minter Ralph
Douthwaite Julie
Bowen Michael
Rust Steve
Moisan Jacques
Privezentzev Cyril
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2014013092A publication Critical patent/MX2014013092A/es
Publication of MX355234B publication Critical patent/MX355234B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425—Zeins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a variantes del antígeno 4 del linfocito T citotóxico (CTLA-4) con una afinidad, potencia y estabilidad elevadas. Formulaciones de variantes de CTLA-4 con una concentración elevada para la administración subcutánea o intravenosa, p. ej., con intervalos de dosificación mensuales o menos frecuentes. Utilización de variantes de CTLA-4 para tratar la artritis reumatoide y otros trastornos inflamatorios. Fusión de CTLA-4 con la región Fc de IgG que tiene una estabilidad mejorada y una semivida in vivo prolongada.
MX2014013092A 2012-05-11 2013-03-11 Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). MX355234B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
PCT/US2013/030179 WO2013169338A1 (en) 2012-05-11 2013-03-11 Ctla-4 variants

Publications (2)

Publication Number Publication Date
MX2014013092A MX2014013092A (es) 2015-03-03
MX355234B true MX355234B (es) 2018-04-11

Family

ID=49551120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013092A MX355234B (es) 2012-05-11 2013-03-11 Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).

Country Status (17)

Country Link
US (2) US9884902B2 (es)
EP (2) EP2863936A4 (es)
JP (1) JP6228971B2 (es)
KR (1) KR102133060B1 (es)
CN (2) CN104302309B (es)
AU (1) AU2013260172B2 (es)
BR (1) BR112014026718B1 (es)
CA (1) CA2868748C (es)
DK (1) DK3207938T3 (es)
ES (1) ES2777778T3 (es)
HK (1) HK1209644A1 (es)
HU (1) HUE048925T2 (es)
MX (1) MX355234B (es)
PL (1) PL3207938T3 (es)
RU (1) RU2671465C2 (es)
SG (2) SG10201609447XA (es)
WO (1) WO2013169338A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302309B (zh) * 2012-05-11 2017-07-28 米迪缪尼有限公司 Ctla‑4变体
EP2867251B1 (en) * 2012-06-29 2019-08-21 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
US9944689B2 (en) * 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
EP3733696A1 (en) * 2015-01-13 2020-11-04 City of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CA2982246A1 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
MX2018003144A (es) * 2015-09-14 2018-09-11 Alpine Immune Sciences Inc Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas.
CR20180318A (es) 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
BR112018070934A2 (pt) 2016-04-15 2019-02-26 Alpine Immune Sciences, Inc. proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
JP2020536552A (ja) * 2017-10-10 2020-12-17 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
MA50404A (fr) 2017-10-18 2020-08-26 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
EP3856247A4 (en) * 2018-11-02 2022-07-06 Beijing Vdjbio Co., Ltd. MODIFIED CTLA4 AND METHODS OF USE
US20220153805A1 (en) * 2019-04-10 2022-05-19 University Of Kentucky Research Foundation A Novel Prostate Apoptosis Response-4 (Par-4) Protein Entity with an Extended Duration of Action for Therapeutic Treatment of Cancer
WO2021142456A1 (en) * 2020-01-11 2021-07-15 Yale University Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
KR20220164569A (ko) * 2020-04-06 2022-12-13 렁 바이오테크놀로지 피비씨 모듈식 합성 수용체 및 사용 방법
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057995A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023112001A2 (en) * 2021-12-17 2023-06-22 Kashiv Biosciences, Llc An improved assay method for determining the potency of recombinant protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP2000515731A (ja) * 1996-06-14 2000-11-28 スミスクライン・ビーチャム・コーポレイション ６量体融合タンパク質およびその使用
GEP20053658B (en) 2000-05-26 2005-11-10 Bristol Myers Squibb Co Soluble CTLA4 Mutant Molecules and Uses Thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP4784772B2 (ja) 2005-07-07 2011-10-05 東芝ライテック株式会社 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
LT2536745T (lt) * 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN104302309B (zh) * 2012-05-11 2017-07-28 米迪缪尼有限公司 Ctla‑4变体

Also Published As

Publication number Publication date
CN104302309B (zh) 2017-07-28
CN107540742B (zh) 2021-06-29
EP2863936A1 (en) 2015-04-29
CN107540742A (zh) 2018-01-05
RU2671465C2 (ru) 2018-10-31
AU2013260172A1 (en) 2014-10-23
DK3207938T3 (da) 2020-03-16
US20180208639A1 (en) 2018-07-26
KR102133060B1 (ko) 2020-07-10
JP2015523328A (ja) 2015-08-13
US9884902B2 (en) 2018-02-06
EP3207938A2 (en) 2017-08-23
ES2777778T3 (es) 2020-08-06
BR112014026718B1 (pt) 2021-05-18
JP6228971B2 (ja) 2017-11-08
KR20150014443A (ko) 2015-02-06
PL3207938T3 (pl) 2020-07-13
HUE048925T2 (hu) 2020-09-28
SG10201609447XA (en) 2017-01-27
SG11201405968SA (en) 2014-11-27
WO2013169338A1 (en) 2013-11-14
CN104302309A (zh) 2015-01-21
HK1209644A1 (en) 2016-04-08
BR112014026718A2 (pt) 2017-07-18
MX2014013092A (es) 2015-03-03
CA2868748A1 (en) 2013-11-14
RU2014150092A (ru) 2016-07-10
CA2868748C (en) 2022-07-26
EP2863936A4 (en) 2016-10-05
US20150104450A1 (en) 2015-04-16
AU2013260172B2 (en) 2017-11-23
EP3207938A3 (en) 2017-11-01
EP3207938B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
MX2014013092A (es) Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
WO2012064627A3 (en) Subcutaneously administered anti-il-6 receptor antibody
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
MX2018013546A (es) Proteinas de fusion de elp para liberacion controlada y sostenida.
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
NZ601114A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
MX355611B (es) Formulaciones de anticuerpos monoclonales de alta concentracion.
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
AU2018205186B2 (en) Angiotensin in treating brain conditions
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
JP2015521607A5 (es)
WO2013016578A3 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
PH12015501815B1 (en) Site-specific insulin conjugate
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
PH12014502596A1 (en) Pharmaceutical formulation
MX2012014479A (es) Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.
WO2014093818A3 (en) Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
PH12017501005A1 (en) Injectable formulations of paracetamol
PH12014502494B1 (en) Parenteral esmolol formulation
Wei et al. CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models
Ricklin et al. Preclinical development and in vivo evaluation of next-generation compstatin analogs with improved systemic profiles: a novel option for the treatment of paroxysmal nocturnal hemoglobinuria

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MEDIMMUNE LIMITED

FG Grant or registration